Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Why does the inner-helix mutation A413C double the stoichiometry of Kv1.3 channel block by emopamil but not by verapamil?

Molecular pharmacology - 1 Apr 2011

Rossokhin Alexey, Dreker Tobias, Grissmer Stephan, Zhorov Boris S

Abstract excerpt

hKv1.3 channels in lymphocytes are targets for the chemotherapy treatment of autoimmune diseases. Phenylalkylamines block Kv1.3 channels by poorly understood mechanisms. In the inactivation-reduced mutant H399T, the second mutation A413C in S6 substantially decreases the potency of phenylalkylamines with a para-methoxy group at the phenylethylamine end, whereas potency of phenylalkylamines lacking this group is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to Chlorocebus aethiops
Share to COS Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cysteine

Share to Hydrogen Bonding

Share to Potassium Channel Blockers

Share to Stereoisomerism

Share to Verapamil

Source

Identifiers

PMID: 21220411
DOI: 10.1124/mol.110.068031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Why does the inner-helix mutation A413C double the stoichiometry of Kv1.3 channel block by emopamil but not by verapamil?PMID 21220411Read ↗

Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state.Semantic proximity Read ↗

An allosteric pocket in KV1.3 defines a distinct chemical space for immunomodulator designSemantic proximity Read ↗

Mutational analysis of ion conduction and drug binding sites in the inner mouth of voltage-gated K+ channels.Semantic proximity Read ↗

The effect of deep pore mutations on the action of phenylalkylamines on the Kv1.3 potassium channel.Semantic proximity Read ↗

Kv1.3 in the spotlight for treating immune diseasesSemantic proximity Read ↗

KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting.Semantic proximity Read ↗

Structural modeling of the hERG potassium channel and associated drug interactionsSemantic proximity Read ↗

Molecular rearrangements of the extracellular vestibule in NMDAR channels during gating.Semantic proximity Read ↗

Effect of verapamil on the action of methanethiosulfonate reagents on human voltage-gated K(v)1.3 channels: implications for the C-type inactivated state.Semantic proximity Read ↗

A side chain in S6 influences both open-state stability and ion permeation in a voltage-gated K+ channel.Semantic proximity Read ↗

Segmental exchanges define 4-aminopyridine binding and the inner mouth of K+ pores.Semantic proximity Read ↗

Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.